Q&A: Gilead public affairs chief on new strategy, TikTok, and why the company won’t ‘keep doing things the same way’
After years of quiet focus on HIV and virology and stoic responses to flare-ups of attention over its pricing decisions, the new Gilead Sciences is ready to talk.
It’s got a revamped public affairs strategy that favors proactivity and aims to own the company’s narrative as it moves into oncology and immunology.
Leading the charge is Alex Kalomparis, senior VP of public affairs at Gilead. Now two years into the role, and seven total years at Gilead, he wants to better tell the story of the biopharma’s groundbreaking health equity work and then translate those lessons into how it communicates in new therapy areas.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.